NKTX at a glance
Nkarta, Inc. (NKTX, SEC CIK 1787400) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Nkarta, Inc. (NKTX) reported revenue of $0 and a net loss of $104.1 million. Diluted EPS was -$1.41.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Nkarta, Inc. (NKTX) shares worth $53.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by HASTINGS PAUL J on June 18, 2026 of 1,776 shares at $2.71 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $53.0M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 7.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, with no product sales since inception
- Operating margin not applicable, net loss $(33.3) million vs $(21.7) million YoY
- NKX019 R&D spending $11.4 million, up from $4.3 million YoY
- Cash, restricted cash and investments $216.0 million as of September 30, 2026
- Operating cash outflow $78.3 million, up from $67.1 million YoY; funding sufficient for at least 12 months
Risk Factors
- Losses $101.5 million, accumulated deficit $749.8 million as of September 30, 2026
- Cash, restricted cash and investments $216.0 million, additional financing needed for pivotal trials
- FDA-agreed amendments enabled outpatient dosing and re-dosing, increasing safety-monitoring and cumulative-toxicity exposure
- Ntrust-1 and Ntrust-2 enrollment challenges from competition for autoimmune trial sites, investigators and patients
- Miltenyi CliniMACS Plus system and reagents remain sole-source manufacturing inputs, with four-to-six-month reagent expiration windows
AI summary of the NKTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- NKX019 initial clinical data released for myositis and systemic sclerosis from the Ntrust trial program
- Data presented at ACR Convergence 2026, providing an external clinical validation forum
Item 8.01: Other Events
- Preliminary NKX019 efficacy signal in myositis: 5/6 patients, 83%, achieved moderate or major responses at 4 billion cells per dose
- Systemic sclerosis results stronger at 4 billion cells: 6/7 patients, 86%, reached rCRISS-25 response or greater by Day 90
Item EX-99.1: Item EX-99.1
- Preliminary NKX019 data support clinical activity in refractory autoimmune disease, strengthening Nkarta’s lead program ahead of regulatory discussions
- Myositis: 5/6 patients achieved moderate or major responses at 4 billion cells per dose, including one sustained TIS 90 response at six months
Item EX-99.2: Item EX-99.2
- NKX019 4B-dose cohort showed 5/6 myositis patients with moderate-to-major TIS responses after ≥3 months
- Systemic sclerosis results: 6/7 achieved rCRISS-25 and 5/7 achieved rCRISS-50 by Day 90
Item 7.01: Regulation FD Disclosure
- Webcast scheduled November 9, 2026 at 8:00 a.m. Eastern Time
- Initial clinical data from NKX019’s Ntrust program in myositis and systemic sclerosis
Item EX-99.1: Item EX-99.1
- Webcast scheduled November 9, 2026 at 8:00 a.m. ET to present initial NKX019 clinical data at ACR Convergence 2026
- Data cover Ntrust trials in myositis and systemic sclerosis, creating a near-term clinical catalyst for NKTX shares
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Full operating and financial details available in Exhibit 99.1, the company’s earnings press release
Item EX-99.1: Item EX-99.1
- Q3 2026 net loss $33.3M, or $0.45 per share, versus $21.7M, or $0.29, in Q3 2025
- R&D spending rose to $29.5M from $20.2M, reflecting accelerated NKX019 clinical development
AI summaries of NKTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NKTX
Don't miss the next NKTX filing
- Alerts as it files. A push when NKTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NKTX, by share count.
- Ask anything. An AI agent that reads every NKTX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| HASTINGS PAUL J | Sell | Jun 18, 2026 | 1,776 | $2.71 |
| Behbahani Ali | A | Jun 10, 2026 | 37,000 | - |
| PATTERSON LEONE D | A | Jun 10, 2026 | 37,000 | - |
| Scheiner Zachary | A | Jun 10, 2026 | 37,000 | - |
| Vratsanos George | A | Jun 10, 2026 | 37,000 | - |
| RA CAPITAL MANAGEMENT, L.P. | A | Jun 10, 2026 | 37,000 | - |
| Thedinga Angela | A | Jun 10, 2026 | 37,000 | - |
| George Simeon | A | Jun 10, 2026 | 37,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $0 |
| Operating Income | - | -$128.2M | -$122.0M |
| Net Income | -$117.5M | -$108.8M | -$104.1M |
| Balance Sheet | |||
| Total Assets | - | $501.2M | $404.2M |
| Equity | - | $408.0M | $312.3M |
| ROE | - | -26.7% | -33.3% |
| Per Share | |||
| EPS | $-2.40 | $-1.60 | $-1.41 |
| Cash Flow | |||
| Operating CF | -$86.2M | -$99.7M | -$88.7M |
| CapEx | $28.1M | $4.4M | $1.2M |
Source: XBRL data in Nkarta, Inc. (NKTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NKTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $53.0M |
| Q2 2026 | 25 | $57.6M |
| Q1 2026 | 24 | $36.4M |
| Q4 2025 | 24 | $29.1M |
| Q3 2025 | 22 | $35.8M |
| Q2 2025 | 22 | $28.0M |
| Q1 2025 | 20 | $27.4M |
| Q4 2024 | 17 | $27.7M |
- BlackRock+547.0K (+9%)
- AQR Capital Management+346.1K (+33%)
- Vanguard Capital Management LLC+137.0K (+6%)
- Morgan Stanley+86.1K (+33%)
- D.E. Shaw & Co+75.3K (+46%)
- Citadel Advisors LLC−476.2K (-22%)
- Renaissance Technologies LLC−378.3K (-32%)
- Two Sigma Investments−185.5K (-10%)
- Millennium Management−108.9K (-34%)
- Goldman Sachs Group−86.4K (-20%)
- StoneX Group Inc.+21.7K
- FMR LLC (Fidelity)−129.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NKTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 26, 2026 | - | - | - |
| 8-K | Mar 25, 2026 | - | - | - |
| 10-K | Mar 25, 2026 | Dec 31, 2025 | - | |
| 4 | Jan 20, 2026 | - | - | |
| 4 | Jan 20, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NKTX SEC filings: frequently asked questions
Which institutions hold NKTX stock?
As of September 30, 2026, the largest Nkarta, Inc. (NKTX) holders among the 13F filers tracked by SignalX were BlackRock ($17.9 million), Vanguard Capital Management LLC ($6.2 million), Citadel Advisors LLC ($4.5 million), Two Sigma Investments ($4.4 million), AQR Capital Management ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NKTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Nkarta, Inc. (NKTX) reported revenue of $0 and a net loss of $104.1 million. Diluted EPS was -$1.41. The figures come from the XBRL data in the 10-K.
What did NKTX report in its latest 8-K?
Nkarta, Inc. (NKTX) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). NKX019 initial clinical data released for myositis and systemic sclerosis from the Ntrust trial program.
What are the latest NKTX SEC filings?
Nkarta, Inc. (NKTX) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on June 22, 2026.
What is NKTX's SEC CIK number?
Nkarta, Inc. (NKTX)'s SEC Central Index Key (CIK) is 1787400. EDGAR lists every NKTX filing under that number.
Ask anything about NKTX
The research agent reads NKTX's filings, financials, insider trades and 13F holders, then answers with sources.